[Application of immune combination therapy in MSS/pMMR-type colorectal cancer: current status and future perspectives].
Zhonghua Zhong Liu Za Zhi
; 46(8): 725-736, 2024 Aug 23.
Article
in Zh
| MEDLINE
| ID: mdl-39143795
ABSTRACT
In recent years, immune checkpoint inhibitors (ICIs) have been widely used in malignant solid tumors with remarkable efficacy. However, in colorectal cancer (CRC), ICIs have shown significant therapeutic effects only in patients with highly microsatellite unstable/mismatch repair-deficient metastatic CRC and these patients are only a minority of all CRC patients. In contrast, the majority of patients, those with microsatellite stable (MSS)/mismatch repair-complete (pMMR)-type metastatic CRC, could hardly benefit from ICI monotherapies, and immune combination therapies have become the key to solveing this clinical challenge. This article introduces the common patterns and possible mechanisms of immune-combination therapies for MSS/pMMR-type CRC, the exploration and progress made in the application of immune-combination therapies, as well as the possible predictive markers of efficacy of immune therapies. The prospects and directions of ICIs in the treatment of MSS/pMMR-type CRC are also discussed.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Colorectal Neoplasms
/
Microsatellite Instability
/
Immune Checkpoint Inhibitors
Limits:
Humans
Language:
Zh
Journal:
Zhonghua Zhong Liu Za Zhi
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: